Last reviewed · How we verify
Viral CTLs
Viral CTLs stimulate the body's immune response to fight viral infections.
Viral CTLs stimulate the body's immune response to fight viral infections. Used for Influenza, Human immunodeficiency virus (HIV), Herpes simplex virus (HSV).
At a glance
| Generic name | Viral CTLs |
|---|---|
| Sponsor | New York Medical College |
| Drug class | Immune modulator |
| Target | CD8+ T cells |
| Modality | Biologic |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
Viral CTLs work by activating cytotoxic T lymphocytes, a type of immune cell that recognizes and kills infected cells. This process helps to eliminate the virus from the body. The exact mechanism of action may vary depending on the specific viral infection being targeted.
Approved indications
- Influenza
- Human immunodeficiency virus (HIV)
- Herpes simplex virus (HSV)
- Human papillomavirus (HPV)
Common side effects
- Fever
- Fatigue
- Headache
- Muscle pain
Key clinical trials
- iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma (PHASE1)
- Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone (PHASE3)
- Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients (PHASE1)
- Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection (PHASE2)
- Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV) (PHASE2)
- CMV CTLs in Neonates With CMV Infection (PHASE2)
- Viral Specific T Cell Therapy for COVID-19 Related Pneumonia (EARLY_PHASE1)
- Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Viral CTLs CI brief — competitive landscape report
- Viral CTLs updates RSS · CI watch RSS
- New York Medical College portfolio CI